Why Genmab’s latest earnings and guidance update matters for investors
Genmab (CPSE:GMAB) reported second quarter 2026 results with higher sales but lower net income compared with a year earlier. The company also raised full year revenue guidance, giving investors an updated view of expected performance.
See our latest analysis for Genmab.
Genmab’s latest earnings release and raised revenue guidance have coincided with strong recent momentum, with a 30 day share price return of 12.57% and a 90 day share price return of 26.98%. Over a longer horizon the 1 year total shareholder return of 39.57% contrasts with weaker 3 and 5 year total shareholder returns, which suggests recent optimism is building off a tougher longer term experience for holders.
If Genmab’s move has you looking at other healthcare related ideas, it could be a useful moment to see which companies are gaining attention in AI driven medicine through our 129 healthcare AI stocks.
After Genmab’s sharp rebound and upgraded revenue guidance, the share price now sits between a low intrinsic value estimate and a higher analyst target. So where does a reasonable fair value range actually land for this stock today?
Most Popular Narrative: 12% Undervalued
Genmab’s most followed narrative places fair value at DKK2,392 per share, above the last close of DKK2,104. This puts the recent rally in a different context for investors reviewing the stock.
Strong recurring royalty streams from established partnered products (such as DARZALEX) and a rising contribution from wholly owned product sales underpin stable, predictable cash flows, providing financial flexibility for pipeline investment and margin expansion.
Want to see what sits behind that confidence in Genmab’s cash flows? The fair value hinges on a specific revenue glide path and a profit profile that shifts meaningfully as the product mix evolves.
Result: Fair Value of DKK2,392 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Genmab’s story still hinges on key uncertainties, including execution against the Darzalex patent expiry gap and the risk of weaker than expected Epkinly trial or approval outcomes.
Find out about the key risks to this Genmab narrative.
Another view on Genmab’s valuation
The fair value narrative suggests Genmab is undervalued, yet the current P/E of 24.7x is above both the European Biotechs average of 23.1x and the peer average of 17.4x, and only slightly above the 24.3x fair ratio. That points to less obvious upside and more valuation risk if expectations slip.
To see what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After weighing both the optimism and the caution in this Genmab update, it may be useful to promptly review the underlying data yourself. A helpful starting point is to compare the 2 key rewards and 3 important warning signs.
Looking for more Genmab style investment ideas?
If Genmab has sharpened your focus, do not stop here. Broader ideas from the Simply Wall St screener can help you stress test your portfolio and spot fresh openings.
- Spot potential mispricings early by scanning 265 high quality undervalued stocks that combine stronger fundamentals with more appealing entry points.
- Strengthen your income stream by reviewing 435 dividend fortresses that pair higher yields with supportive financial profiles.
- Dial back portfolio risk by checking 290 resilient stocks with low risk scores that show more resilient balance sheets and steadier business characteristics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com